ENDPOINTS NEWS35m
CSL Behring will close Cal­i­for­nia of­fice as part of shrink­ing ex vi­vo work
CSL Behring is closing its Pasadena R&D site, relocating operations to Waltham, Massachusetts, affecting 30 employees. The ...
ENDPOINTS NEWS8m
Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study
Rocket Pharmaceuticals reported Monday that benefits from its Danon disease gene therapy were seen up to around five years after treatment.
ENDPOINTS NEWS43m
Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study
Neurogene reported a patient experienced systemic hyperinflammatory syndrome during their Rett syndrome gene therapy trial. CEO Rachel McMinn confirmed the female patient is in critical condition. The ...